India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford University Covid-19 vaccine candidate.
source https://timesofindia.indiatimes.com/india/serum-gets-dcgi-nod-for-phase-2-3-trials/articleshow/77340150.cms
0 Comments:
Post a Comment